VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit
- PMID: 33284652
- DOI: 10.1161/CIRCULATIONAHA.120.050512
VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit
Keywords: Editorials; cardiovascular diseases; diabetes mellitus, type 2; heart failure; sodium-glucose transporter 2 inhibitors.
Comment on
-
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.Circulation. 2020 Dec 8;142(23):2205-2215. doi: 10.1161/CIRCULATIONAHA.120.050255. Epub 2020 Oct 7. Circulation. 2020. PMID: 33026243 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
